Acinetobacter Baumannii News and Research

RSS

Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to AR-301, the Company's fully human anti-Staphylococcal alpha-toxin IgG1 monoclonal antibody (mAb).

11 Sep 2015

Multidrug-resistant bacteria can naturally relinquish its ability to resist antibiotics

Infections with one of the most troublesome and least understood antibiotic-resistant "superbugs" are increasing at alarming rates, particularly in health-care settings.

14 Jul 2015

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains.

8 Jul 2015

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to its fully human monoclonal antibody Aerucin for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

30 Jun 2015

Common antibiotic azithromycin effectively kills many multidrug-resistant bacteria

Contrary to current medical dogma, researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences report that the common antibiotic azithromycin kills many multidrug-resistant bacteria very effectively — when tested under conditions that closely resemble the human body and its natural antimicrobial factors.

11 Jun 2015

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, today announced the presentation of data demonstrating the promise of its lead clinical candidate, TXA709, in combating antibiotic resistance.

27 Apr 2015

NIAID funds nine research projects to advance rapid diagnostics tests for drug-resistant bacteria

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded more than $11 million in first-year funding for nine research projects supporting enhanced diagnostics to rapidly detect antimicrobial-resistant bacteria.

10 Apr 2015

Aridis Pharmaceuticals begins Aerucin Phase 1 clinical study for treatment of acute pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the initiation of a Phase 1 clinical study of Aerucin, the Company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia.

26 Mar 2015

New NIH grant to support development of rapid method for diagnosing mucormycosis

Speed is essential in treating deadly mucormycosis fungal infections, but a quick diagnosis is difficult because no routine blood test exists.

19 Feb 2015

Antibiotic stewardship programs reduce hospital readmissions due to infection

Antibiotic stewardship programs, which promote the appropriate use of antibiotics in hospitals and other healthcare centers, not only lead to reduction in antibiotic use with reduced adverse events, but also lead to significant savings.

8 Sep 2014

New research unit to uncover multi-drug resistant bacteria in hospitals

Multi-drug resistant bacteria have increased dramatically in hospitals in recent years and present immense challenges to staff and patients, often with fatal results.

8 Jul 2014

New rapid diagnostic test for multi-resistance to broad-spectrum antibiotics

A rapid diagnostic test for multi-resistance to broad-spectrum antibiotics has just been developed at the University of Fribourg. Prof Patrice Nordmann and Dr Laurent Poirel of the Medical and Molecular Microbiology Unit have been collaborating with Unit 914 of the National Institute of Health and Medical Research (INSERM) in Paris, of which Patrice Nordmann is also Director.

26 Jun 2014

Scientists turn to old class of antibiotics to fight superbugs resistant to modern medicine

Scientists at the University at Buffalo are turning to an old class of antibiotics to fight new superbugs resistant to modern medicine.

24 Jun 2014

Cepheid releases molecular test for detection of carbapenemase-producing Gram-negative bacteria

Cepheid today announced the release of Xpert® Carba-R, an on-demand molecular test for rapid and accurate detection of carbapenemase-producing Gram-negative bacteria, to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices.

16 Jun 2014

Findings have important implications for improving war wound healing

War wounds that heal successfully frequently contain different microbial species from those that heal poorly, according to a paper published ahead of print in the Journal of Clinical Microbiology.

30 May 2014

MGH researchers test novel approach to disinfecting wounds in animal study

Application of a technology currently used to disinfect food products may help to get around one of the most challenging problems in medicine today, the proliferation of bacteria resistant to antibiotics and other antimicrobial drugs.

22 May 2014

Seward highlights effectiveness of Stomacher technique and sponge swabs for hygiene monitoring

Seward Ltd., manufacturers of the world leading range of Stomacher paddle blenders and Stomacher® accessories used in sample preparation for microbiological analyses, have highlighted the highly effective use of its Stomacher technology in combination with sponge swabs for hygiene monitoring and biosecurity applications.

28 Jan 2014

FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections

FOB Synthesis, Inc. has entered into a research and development option and license agreement with AstraZeneca for the development of a novel antibiotic to treat drug-resistant bacterial infections.

28 Jan 2014

Researchers identify resistance protein that allows bacteria to survive chlorhexidine

Researchers have identified a resistance protein that allows bacteria to survive chlorhexidine, a disinfectant commonly used in wipes, cleansers and mouthwashes in hospitals.

4 Dec 2013

FDA promise to "reboot" antibiotic development rules to combat rise in resistance falls short

The rise of antibiotic resistance among hospital-acquired infections is greater than the Centers for Disease Control and Prevention found in its 2008 analysis, according to an ahead-of-print article in the journal, Antimicrobial Agents and Chemotherapy.

2 Aug 2013